TruSpine Technologies Plc — Capital/Financing Update 2021

Mar 30, 2021

National Storage Mechanism | Additional information

RNS Number : 8818T

TruSpine Technologies PLC

30 March 2021

TruSpine Technologies plc

("TruSpine" or the "Company")

Proposed Equity Fundraise

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused in the spinal (vertebral) stabilisation market, announces that it is in discussions to raise up to £750,000 by way of an equity fundraise, at a price of £0.10 per share with a warrant for each share subscribed or placed exercisable at £0.15 per share for a period of three years.

There is no certainty nor guarantee that the proposed equity fundraise will complete successfully nor on the same terms described above.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

Truspine Technologies Plc		Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Adviser)			Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
WH Ireland (Broker)		Tel: +44 (0)20 7220 1666
Adam Pollock
Walbrook PR (Financial PR & IR)	Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Anna Dunphy		[email protected]

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiÞed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reßect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFFFFLVFIAFIL